|
Avacta Group PLC on Monday announced the opening of a phase 1 trial for AVA6103, a peptide-drug conjugate. The London-based life sciences company said the conjugate will be evaluated regarding its efficacy in patients diagnosed with one of four solid tumours for the advanced setting, namely pancreatic cancer, cervical and vulvar cancer, as well as gastric and gastroesophageal junction cancers, and small cell lung cancer. The first patient is expected to enrol in the study before the end of this month, with preliminary safety and pharmacokinetic data anticipated in the second half of 2026. Christina Coughlin, chief executive officer of Avacta Therapeutics, said: ‘The opening of the first clinical sites in the phase 1 trial of AVA6103 is an important milestone. It is notable that this program continues to move into clinical development faster than normal industry timelines. With our proprietary sustained release mechanism, we expect AVA6103 to enable greater efficacy from the exatecan payload while limiting the severe toxicities that were observed in the initial development of this payload in the clinic.’ Avacta shares rose 3.4% to 73.41 pence each on Monday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
